cht101
Cell therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 19, 2024 (NCT06730659)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Carcinoma, Renal Cell · Phase 1
- Lupus Erythematosus, Systemic · Early Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, T-Cell · Phase 1
- Lymphoma, T-Cell, Peripheral · Phase 1
- Nasopharyngeal Carcinoma · Phase 1
- Neoplasm Metastasis · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- CD70 antigenImmunity, passive
CD70 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06946485 | Early Phase 1 (Phase 1) | Apr 1, 2025 | Nanjing University |
| NCT06914037 | Phase 1 | Mar 31, 2025 | Government of China, Tianjin Medical University |
| NCT06383507 | Phase 1 | Apr 22, 2024 | Zhejiang University |
| NCT06730659 | Phase 1 | Apr 19, 2024 | Government of China, Tianjin Medical University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 2 | 0 | 1 | 2024 |
| Tianjin Medical University | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Nanjing University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2024 |
4 organizations
Page 1 / 1